SlideShare a Scribd company logo
Plaque Rupture: Definition
Structural failure of the fibrocellular cap11
that
separates an atheromatous core22
from the lumen
of an atherosclerotic artery (ie, lumen ↔ core).
11
cap defect/gapcap defect/gap rupture, fissure, break, tear
not just missing endotheliumnot just missing endothelium
22
lipid-richlipid-rich Greek athere, gruel (soft)
Propensity to rupture
 lipid-rich corelipid-rich core + → +++
no coreno core →→ no capno cap -
Plaque Rupture: Definition
Plaque rupture ≠ Plaque disruption
Plaque rupture
Plaque erosion
Endothelial
disruption
Plaque Rupture: Definition
Plaque rupture ≠ Plaque disruption
Plaque rupture
Plaque erosion
Endothelial
disruption
Cardiovascular Risk Factors
athero-thrombosisathero-thrombosis
Traditional age and sex
cholesterol, LDL vs HDL
diabetes (metabolic syndrome/exercise)
smoking
hypertension
family history
Novel inflammation: CRP, fibrinogen, IL, etc
infection: Cp, CMV, HSV, Hp, ’burden’
homocysteine, folate, B6
coronary calcium: EBCT, IVUS
carotid IMT
Plaque Rupture → Fatal Thrombosis
1460 coronary thrombi1460 coronary thrombi
Patients Age n Rupture Study
Hospital, ? ? 19 19 = 100% Chapman-
1965
Hospital, ? ? 17 17 = 100%
Constantinides-1966
Hospital, AMI+SCD 58 y 40 39 = 98% Friedman-1966
Hospital, AMI 62 y 88 71 = 81% Bouch-1970
Hospital, AMI 66 y 91 68 = 75% Sinapius-1972
Coroner, SCD 53 y 20 19 = 95% Friedman-1973
Hospital, AMI 67 y 76 69 = 91% Horie-1978
Hospital, AMI 67 y 49 40 = 82% Falk-1983
Coroner, SCD <65 y 32 26 = 81% Tracy-1985
Med.exam, SCD <70 y 61 39 = 64% El Fawal-1987
Hospital, AMI 83 52 = 63% Yutani-1987
Coroner, SCD? ? 85 71 = 84% Richardson-1989
Hospital, AMI 63 y 20 12 = 60% van der Wal-1994
Coroner, SCD (all?) ? 202 143 = 71% Davies-1997,
update
Hospital, AMI 69 y 291 218 = 75% Arbustini-1999
Hospital, AMI 61 y 61 56 = 92% Shi-1999
Hospital, AMI 69 y 100 81 = 81% Kojima-2000
Plaque Rupture → Fatal Thrombosis
EuropeEurope ≈≈ AsiaAsia ≈≈ USAUSA
Patients Age n Rupture Study
Hospital, AMI 62 y 88 71 = 81% Bouch-1970
Hospital, AMI 66 y 91 68 = 75% Sinapius-
1972
Hospital, AMI 67 y 49 40 = 82% Falk-1983
Med.exam, SCD <70 y 61 39 = 64% El Fawal-
1987
Coroner, SCD? ? 85 71 = 84% Richardson-
1989
Hospital, AMI 63 y 20 12 = 60% van der Wal-
1994
Coroner, SCD (all?) ? 202 143 = 71% Davies-1997,
update
Hospital, AMI 69 y 291 218 = 75% Arbustini-
1999
887 662 = 75% Europe
Hospital, AMI 67 y 76 69 = 91% Horie-1978
Hospital, AMI 83 52 = 63% Yutani-1987
Hospital, AMI 61 y 61 56 = 92% Shi-1999
Hospital, AMI 69 y 100 81 = 81% Kojima-2000
320 258 = 81% Asia
Plaque Rupture → Fatal Thrombosis
AsiaAsia:: JapanJapan ≈≈ ChinaChina
Patients Age n Rupture Study
Hospital, AMI 62 y 88 71 = 81% Bouch-1970
Hospital, AMI 66 y 91 68 = 75% Sinapius-
1972
Hospital, AMI 67 y 49 40 = 82% Falk-1983
Med.exam, SCD <70 y 61 39 = 64% El Fawal-
1987
Coroner, SCD? ? 85 71 = 84% Richardson-
1989
Hospital, AMI 63 y 20 12 = 60% van der Wal-
1994
Coroner, SCD (all?) ? 202 143 = 71% Davies-1997,
update
Hospital, AMI 69 y 291 218 = 75% Arbustini-
1999
887 662 = 75% Europe
Hospital, AMI 76 69 = 91% Horie-
Japan
Hospital, AMI 83 52 = 63% Yutani-
Japan
Hospital, AMI 61 56 = 92% Shi-
China
Hospital, AMI 100 81 = 81% Kojima-
Plaque Rupture → Fatal Thrombosis
hospitalhospital ≈≈ coroner/med.exam.coroner/med.exam.
Patients Age n Rupture Study
Hospital, ? ? 19 19 = 100% Chapman-
1965
Hospital, ? ? 17 17 = 100%
Constantinides-1966
Hospital, AMI+SCD 58 y 40 39 = 98% Friedman-
1966
Hospital, AMI 62 y 88 71 = 81% Bouch-1970
Hospital, AMI 66 y 91 68 = 75% Sinapius-
1972
Hospital, AMI 67 y 76 69 = 91% Horie-1978
Hospital, AMI 67 y 49 40 = 82% Falk-1983
Hospital, AMI 83 52 = 63% Yutani-1987
Hospital, AMI 63 y 20 12 = 60% van der Wal-
1994
Hospital, AMI 69 y 291 218 = 75% Arbustini-
1999
Hospital, AMI 61 y 61 56 = 92% Shi-1999
Hospital, AMI 69 y 100 81 = 81% Kojima-2000
935 742 = 79% Hospital
Coroner, SCD 53 y 20 19 = 95% Friedman-
1973
Coroner, SCD <65 y 32 26 = 81% Tracy-1985
Med.exam, SCD <70 y 61 39 = 64% El Fawal-
Plaque Rupture → Fatal Thrombosis
acute MIacute MI ≈≈ sudden deathsudden death
Patients Age n Rupture Study
Hospital, ? ? 19 19 = 100% Chapman-
1965
Hospital, ? ? 17 17 = 100%
Constantinides-1966
Hospital, AMI+SCD 58 y 40 39 = 98% Friedman-
1966
Hospital, AMI 62 y 88 71 = 81% Bouch-1970
Hospital, AMI 66 y 91 68 = 75% Sinapius-
1972
Hospital, AMI 67 y 76 69 = 91% Horie-1978
Hospital, AMI 67 y 49 40 = 82% Falk-1983
Hospital, AMI 83 52 = 63% Yutani-1987
Hospital, AMI 63 y 20 12 = 60% van der Wal-
1994
Hospital, AMI 69 y 291 218 = 75% Arbustini-
1999
Hospital, AMI 61 y 61 56 = 92% Shi-1999
Hospital, AMI 69 y 100 81 = 81% Kojima-2000
935 742 = 79% Acute MI
Coroner, SCD 53 y 20 19 = 95% Friedman-
1973
Coroner, SCD <65 y 32 26 = 81% Tracy-1985
Med.exam, SCD <70 y 61 39 = 64% El Fawal-
Plaque Rupture → Fatal Thrombosis
age of deceasedage of deceased
Patients Age n Rupture Study
Hospital, ? ? 19 19 = 100% Chapman-
1965
Hospital, ? ? 17 17 = 100%
Constantinides-1966
Hospital, AMI 83 52 = 63% Yutani-1987
Coroner, SCD? ? 85 71 = 84% Richardson-
1989
Coroner, SCD (all?) ? 202 143 = 71% Davies-1997,
update
406 302 = 74% Age
unknown
Hospital, AMI 62 y 88 71 = 81% Bouch-1970
Hospital, AMI 66 y 91 68 = 75% Sinapius-
1972
Hospital, AMI 67 y 76 69 = 91% Horie-1978
Hospital, AMI 67 y 49 40 = 82% Falk-1983
Med.exam, SCD <70 y 61 39 = 64% El Fawal-
1987
Hospital, AMI 63 y 20 12 = 60% van der Wal-
1994
Hospital, AMI 69 y 291 218 = 75% Arbustini-
1999
Hospital, AMI 61 y 61 56 = 92% Shi-1999
Hospital, AMI 69 y 100 81 = 81% Kojima-2000
837 654 = 78% >60 years
Plaque Rupture → Fatal Thrombosis
sexsex
Sex n Rupture Study
p
Male 37 32 = 86% Falk-1983
134 113 = 84% Davies-1997
184 151 = 82% Arbustini-
1999 .0004
74 63 = 85% Kojima-2000
.08 → .4
94 64 = 68% Virmani-
2000, update
523 423 = 81%
Female 12 8 = 67% Falk-1983
27 16 = 59% Davies-1997
107 67 = 63% Arbustini-
1999
26 18 = 69% Kojima-2000
31 10 = 32% Virmani-
2000, update
Plaque Rupture → Fatal Thrombosis
sexsex && ageage
Sex Age, y n Rupture Study
Male >41, all 37 86% Falk-
1983
<50 7 86%
-------------
+12 Females 50-70 22 82%
-------------
>70 20 80%
-------------
Male ~47 59 69%
Burke-1997
unrelated to age
Plaque Rupture → Fatal Thrombosis
sexsex && ageage
Sex Age, y n Rupture Study
Male >41, all 37 86% Falk-
1983
<50 7 86%
-------------
+12 Females 50-70 22 82%
-------------
>70 20 80%
-------------
Male ~47 59 69%
Burke-1997
unrelated to age
Plaque Rupture → Coronary Thrombosis
burden of CHDburden of CHD
*MI + fatal CHD. AHA 2002 Heart and Stroke Statistical Update.
Annual heart attacks in the US: 1,107,000*
• Men 668,000
Women,
• ≥45 y
430,000
• <45 y 9,000
39%
<1%
60%
Plaque Rupture → Coronary Thrombosis
burden of CHDburden of CHD
Annual heart attacks in the US: 1,107,000
Plaque erosionPlaque erosion
is the major substrate
for thrombosis in
premenopausal women.
Burke et al. Am Heart J 2001
39%
60%
~1%
Plaque Rupture → Coronary Thrombosis
burden of CHDburden of CHD
Annual heart attacks in the US: 1,107,000
Plaque erosionPlaque erosion
is the major substrate
for thrombosis in
premenopausal women.
Burke et al. Am Heart J 2001
Plaque rupturePlaque rupture
is the major substrate
in postmenopausal
women and men
~1%
Fatal Thrombosis: Rupture vs Non-rupture
ageage && sexsex
Rupture
+ - Study
p
Age, mean
53 y 44 y Farb-1996
<.02
68 y 70 y Arbustini-
1999 NS
69 y 71 y Kojima-2000
NS
Male 48 y 45 y Burke-1997
NS
Fatal Thrombosis: Rupture vs Non-rupture
ageage && sexsex
Rupture
+ - Study
p
Age, mean
53 y 44 y Farb-1996
<.02
68 y 70 y Arbustini-
1999 NS
69 y 71 y Kojima-2000
NS
Male 48 y 45 y Burke-1997
NS
Fatal Thrombosis: Rupture vs Non-rupture
whites vs blackswhites vs blacks
Rupture
+ - Study
p
Race
Race was not significantly (p>0.4)
associated with plaque rupture in men*
*Burke AP et al. N Engl J Med 1997;336:1276-82
Fatal Thrombosis: Rupture vs Non-rupture
hypercholesterolemiahypercholesterolemia
Rupture
+ - Study
p
Cholesterol
Male
mg/dlmg/dl 262 220 Burke-1997
.003
totaltotal::HDLHDL 8.5 5.0 Burke-1997
.003
Female
mg/dlmg/dl 270 188 Burke-1998
.007
totaltotal::HDLHDL 6.2 6.0 Burke-1998
NS
Fatal Thrombosis: Rupture vs Non-rupture
hypertensionhypertension
Rupture
+ - Study
p
Hypertension
22% 11% Burke-1997
NS
38% 22% Burke-1998
NS
56% 58% Kojima-2000
NS
Fatal Thrombosis: Rupture vs Non-rupture
diabetes mellitus ~ type 2diabetes mellitus ~ type 2
Rupture
n + - Study
p
Diabetes
8 13% 33% Falk-1983
41 11% 64% Davies-1996,
Circ
57 61% 42% Kojima-2000
NS
GlycoHgb
59 7.9% 6.9% Burke-1997
NS
Fatal Thrombosis: Rupture vs Non-rupture
diabetes mellitus ~ type 2diabetes mellitus ~ type 2
Rupture
n + - Study
p
Diabetes
8 13% 33% Falk-1983
41 11% 64% Davies-1996,
Circ
5757 61%61% 42%42% Kojima-2000Kojima-2000
NSNS
GlycoHgb
5959 7.9%7.9% 6.9%6.9% Burke-1997Burke-1997
NSNS
Fatal Thrombosis: Rupture vs Non-rupture
cigarette smokingcigarette smoking
Rupture
+ - Study
p
Smokers
71% 83% Burke-1997
NS
50% 78% Burke-1998
NS
62% 26% Kojima-2000
.04
Fatal Thrombosis: Rupture vs Non-rupture
local flow and shearlocal flow and shear
Rupture
+ - Study
p
Stenosis, mean
area, %area, % 91 93 Falk-1983
NS
78 70 Farb-1996
<.03
77 70 Burke-1998
NS
76 70 Kojima-
2000 NS
diameter, %diameter, % 39 64 Davies-
Fatal Thrombosis: Rupture vs Non-rupture
plaque calcificationplaque calcification
Rupture
+ - Study
p
Calcification
69% 23% Farb-1996
.002
Plaque Rupture → Fatal Thrombosis
exertion and sudden deathexertion and sudden death
Coronary thrombosis in men
n Rupture
Study
Acute exertion
+ 19 89%
Burke*
- 51 53%
--------
*Burke et al. JAMA 1999;281:921-26
Coronary Thrombosis: Virchow’s triad
pathogenesispathogenesis
Local Systemic = Blo
substrate flow coag.–plts.–fibr.lysis
queque
uptureupture +++ +
on-ruptureon-rupture + +++ +++
Coronary Thrombosis: Virchow’s triad
therapytherapy
Local Systemic = Blo
substrate flow coag.–plts.–fibr.lysis
queque
uptureupture +++ +
on-ruptureon-rupture + +++ +++
Statins ASA, clopidogrel, warfarin, etc.
? ?
Coronary Thrombosis: Virchow’s triad
therapytherapy
Local Systemic = Blo
substrate flow coag.–plts.–fibr.lysis
queque
uptureupture +++ +
on-ruptureon-rupture + +++ +++
Statins ASA, clopidogrel, warfarin, etc.
? ?
Additive?Additive?Additive?Additive?
lipid-rich core
thrombus
cap
cap

More Related Content

Viewers also liked

8
88
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understanding
SHAPE Society
 
105 nir spectroscopy studies
105 nir spectroscopy studies105 nir spectroscopy studies
105 nir spectroscopy studies
SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
SHAPE Society
 
183 postulated mechanisms of insulin resistance
183 postulated mechanisms of insulin resistance183 postulated mechanisms of insulin resistance
183 postulated mechanisms of insulin resistance
SHAPE Society
 
114 evaluation of atherosclerotic plaque
114 evaluation of atherosclerotic plaque114 evaluation of atherosclerotic plaque
114 evaluation of atherosclerotic plaque
SHAPE Society
 
3rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 13rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 1
SHAPE Society
 
198 pulse sequences
198 pulse sequences198 pulse sequences
198 pulse sequences
SHAPE Society
 
134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging
SHAPE Society
 
230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crp
SHAPE Society
 
074 influenza infection effects
074 influenza infection effects074 influenza infection effects
074 influenza infection effects
SHAPE Society
 
144 physics of mri
144 physics of mri144 physics of mri
144 physics of mri
SHAPE Society
 
117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteries
SHAPE Society
 
238 carotid array coil
238 carotid array coil238 carotid array coil
238 carotid array coil
SHAPE Society
 
031
031031
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
SHAPE Society
 
3rd vulnerable plaque rumberger 3 16-02 4
3rd vulnerable plaque rumberger 3 16-02 43rd vulnerable plaque rumberger 3 16-02 4
3rd vulnerable plaque rumberger 3 16-02 4
SHAPE Society
 
218 pharmacologic stabilization of vulnerable plaque
218 pharmacologic stabilization of vulnerable plaque218 pharmacologic stabilization of vulnerable plaque
218 pharmacologic stabilization of vulnerable plaque
SHAPE Society
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosis
SHAPE Society
 
219 coronary autoregulation in vivo
219 coronary autoregulation in vivo219 coronary autoregulation in vivo
219 coronary autoregulation in vivo
SHAPE Society
 

Viewers also liked (20)

8
88
8
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understanding
 
105 nir spectroscopy studies
105 nir spectroscopy studies105 nir spectroscopy studies
105 nir spectroscopy studies
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
183 postulated mechanisms of insulin resistance
183 postulated mechanisms of insulin resistance183 postulated mechanisms of insulin resistance
183 postulated mechanisms of insulin resistance
 
114 evaluation of atherosclerotic plaque
114 evaluation of atherosclerotic plaque114 evaluation of atherosclerotic plaque
114 evaluation of atherosclerotic plaque
 
3rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 13rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 1
 
198 pulse sequences
198 pulse sequences198 pulse sequences
198 pulse sequences
 
134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging134 mr contrast agents for vulnerable plaque imaging
134 mr contrast agents for vulnerable plaque imaging
 
230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crp
 
074 influenza infection effects
074 influenza infection effects074 influenza infection effects
074 influenza infection effects
 
144 physics of mri
144 physics of mri144 physics of mri
144 physics of mri
 
117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteries
 
238 carotid array coil
238 carotid array coil238 carotid array coil
238 carotid array coil
 
031
031031
031
 
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
204 prevalence of inflammatory cells in non ruptured atherosclerotic plaques
 
3rd vulnerable plaque rumberger 3 16-02 4
3rd vulnerable plaque rumberger 3 16-02 43rd vulnerable plaque rumberger 3 16-02 4
3rd vulnerable plaque rumberger 3 16-02 4
 
218 pharmacologic stabilization of vulnerable plaque
218 pharmacologic stabilization of vulnerable plaque218 pharmacologic stabilization of vulnerable plaque
218 pharmacologic stabilization of vulnerable plaque
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosis
 
219 coronary autoregulation in vivo
219 coronary autoregulation in vivo219 coronary autoregulation in vivo
219 coronary autoregulation in vivo
 

Similar to 154 plaque rupture definition

20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
SHCI - Sección de Hemodinámica y Cardiología Intervencionista
 
Heart failure syndrom ekfhexp
Heart failure syndrom ekfhexpHeart failure syndrom ekfhexp
Heart failure syndrom ekfhexp
asadsoomro1960
 
Which Chest Pain Can Be Safely Discharged From Ed
Which Chest Pain Can Be Safely Discharged From EdWhich Chest Pain Can Be Safely Discharged From Ed
Which Chest Pain Can Be Safely Discharged From Ed
Rashidi Ahmad
 
Heart rate a global target for cardiovascular disease and therapy along the c...
Heart rate a global target for cardiovascular disease and therapy along the c...Heart rate a global target for cardiovascular disease and therapy along the c...
Heart rate a global target for cardiovascular disease and therapy along the c...
Kyaw Win
 
Presentation STATS.pptx
Presentation STATS.pptxPresentation STATS.pptx
Presentation STATS.pptx
MaharijNoor
 
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Chaichuk Sergiy
 
Cardiac petct ahmed tawakol
Cardiac petct ahmed tawakolCardiac petct ahmed tawakol
conference presentation of your reseach
conference presentation of your reseachconference presentation of your reseach
conference presentation of your reseach
Ramachandra Barik
 
Post partum cardiomyopathypptx
Post partum cardiomyopathypptxPost partum cardiomyopathypptx
Post partum cardiomyopathypptx
NikoYuandika
 

Similar to 154 plaque rupture definition (9)

20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
 
Heart failure syndrom ekfhexp
Heart failure syndrom ekfhexpHeart failure syndrom ekfhexp
Heart failure syndrom ekfhexp
 
Which Chest Pain Can Be Safely Discharged From Ed
Which Chest Pain Can Be Safely Discharged From EdWhich Chest Pain Can Be Safely Discharged From Ed
Which Chest Pain Can Be Safely Discharged From Ed
 
Heart rate a global target for cardiovascular disease and therapy along the c...
Heart rate a global target for cardiovascular disease and therapy along the c...Heart rate a global target for cardiovascular disease and therapy along the c...
Heart rate a global target for cardiovascular disease and therapy along the c...
 
Presentation STATS.pptx
Presentation STATS.pptxPresentation STATS.pptx
Presentation STATS.pptx
 
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
 
Cardiac petct ahmed tawakol
Cardiac petct ahmed tawakolCardiac petct ahmed tawakol
Cardiac petct ahmed tawakol
 
conference presentation of your reseach
conference presentation of your reseachconference presentation of your reseach
conference presentation of your reseach
 
Post partum cardiomyopathypptx
Post partum cardiomyopathypptxPost partum cardiomyopathypptx
Post partum cardiomyopathypptx
 

More from SHAPE Society

Barth imt
Barth imtBarth imt
Barth imt
SHAPE Society
 
Braunwald
BraunwaldBraunwald
Braunwald
SHAPE Society
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
SHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
SHAPE Society
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
SHAPE Society
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
SHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
SHAPE Society
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
SHAPE Society
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
SHAPE Society
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
SHAPE Society
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
SHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
SHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
SHAPE Society
 
A20 gene
A20 geneA20 gene
A20 gene
SHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
SHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
SHAPE Society
 
103100
103100103100
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
SHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 

Recently uploaded

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Traumasoft LLC
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 

154 plaque rupture definition

  • 1. Plaque Rupture: Definition Structural failure of the fibrocellular cap11 that separates an atheromatous core22 from the lumen of an atherosclerotic artery (ie, lumen ↔ core). 11 cap defect/gapcap defect/gap rupture, fissure, break, tear not just missing endotheliumnot just missing endothelium 22 lipid-richlipid-rich Greek athere, gruel (soft) Propensity to rupture  lipid-rich corelipid-rich core + → +++ no coreno core →→ no capno cap -
  • 2. Plaque Rupture: Definition Plaque rupture ≠ Plaque disruption Plaque rupture Plaque erosion Endothelial disruption
  • 3. Plaque Rupture: Definition Plaque rupture ≠ Plaque disruption Plaque rupture Plaque erosion Endothelial disruption
  • 4. Cardiovascular Risk Factors athero-thrombosisathero-thrombosis Traditional age and sex cholesterol, LDL vs HDL diabetes (metabolic syndrome/exercise) smoking hypertension family history Novel inflammation: CRP, fibrinogen, IL, etc infection: Cp, CMV, HSV, Hp, ’burden’ homocysteine, folate, B6 coronary calcium: EBCT, IVUS carotid IMT
  • 5. Plaque Rupture → Fatal Thrombosis 1460 coronary thrombi1460 coronary thrombi Patients Age n Rupture Study Hospital, ? ? 19 19 = 100% Chapman- 1965 Hospital, ? ? 17 17 = 100% Constantinides-1966 Hospital, AMI+SCD 58 y 40 39 = 98% Friedman-1966 Hospital, AMI 62 y 88 71 = 81% Bouch-1970 Hospital, AMI 66 y 91 68 = 75% Sinapius-1972 Coroner, SCD 53 y 20 19 = 95% Friedman-1973 Hospital, AMI 67 y 76 69 = 91% Horie-1978 Hospital, AMI 67 y 49 40 = 82% Falk-1983 Coroner, SCD <65 y 32 26 = 81% Tracy-1985 Med.exam, SCD <70 y 61 39 = 64% El Fawal-1987 Hospital, AMI 83 52 = 63% Yutani-1987 Coroner, SCD? ? 85 71 = 84% Richardson-1989 Hospital, AMI 63 y 20 12 = 60% van der Wal-1994 Coroner, SCD (all?) ? 202 143 = 71% Davies-1997, update Hospital, AMI 69 y 291 218 = 75% Arbustini-1999 Hospital, AMI 61 y 61 56 = 92% Shi-1999 Hospital, AMI 69 y 100 81 = 81% Kojima-2000
  • 6. Plaque Rupture → Fatal Thrombosis EuropeEurope ≈≈ AsiaAsia ≈≈ USAUSA Patients Age n Rupture Study Hospital, AMI 62 y 88 71 = 81% Bouch-1970 Hospital, AMI 66 y 91 68 = 75% Sinapius- 1972 Hospital, AMI 67 y 49 40 = 82% Falk-1983 Med.exam, SCD <70 y 61 39 = 64% El Fawal- 1987 Coroner, SCD? ? 85 71 = 84% Richardson- 1989 Hospital, AMI 63 y 20 12 = 60% van der Wal- 1994 Coroner, SCD (all?) ? 202 143 = 71% Davies-1997, update Hospital, AMI 69 y 291 218 = 75% Arbustini- 1999 887 662 = 75% Europe Hospital, AMI 67 y 76 69 = 91% Horie-1978 Hospital, AMI 83 52 = 63% Yutani-1987 Hospital, AMI 61 y 61 56 = 92% Shi-1999 Hospital, AMI 69 y 100 81 = 81% Kojima-2000 320 258 = 81% Asia
  • 7. Plaque Rupture → Fatal Thrombosis AsiaAsia:: JapanJapan ≈≈ ChinaChina Patients Age n Rupture Study Hospital, AMI 62 y 88 71 = 81% Bouch-1970 Hospital, AMI 66 y 91 68 = 75% Sinapius- 1972 Hospital, AMI 67 y 49 40 = 82% Falk-1983 Med.exam, SCD <70 y 61 39 = 64% El Fawal- 1987 Coroner, SCD? ? 85 71 = 84% Richardson- 1989 Hospital, AMI 63 y 20 12 = 60% van der Wal- 1994 Coroner, SCD (all?) ? 202 143 = 71% Davies-1997, update Hospital, AMI 69 y 291 218 = 75% Arbustini- 1999 887 662 = 75% Europe Hospital, AMI 76 69 = 91% Horie- Japan Hospital, AMI 83 52 = 63% Yutani- Japan Hospital, AMI 61 56 = 92% Shi- China Hospital, AMI 100 81 = 81% Kojima-
  • 8. Plaque Rupture → Fatal Thrombosis hospitalhospital ≈≈ coroner/med.exam.coroner/med.exam. Patients Age n Rupture Study Hospital, ? ? 19 19 = 100% Chapman- 1965 Hospital, ? ? 17 17 = 100% Constantinides-1966 Hospital, AMI+SCD 58 y 40 39 = 98% Friedman- 1966 Hospital, AMI 62 y 88 71 = 81% Bouch-1970 Hospital, AMI 66 y 91 68 = 75% Sinapius- 1972 Hospital, AMI 67 y 76 69 = 91% Horie-1978 Hospital, AMI 67 y 49 40 = 82% Falk-1983 Hospital, AMI 83 52 = 63% Yutani-1987 Hospital, AMI 63 y 20 12 = 60% van der Wal- 1994 Hospital, AMI 69 y 291 218 = 75% Arbustini- 1999 Hospital, AMI 61 y 61 56 = 92% Shi-1999 Hospital, AMI 69 y 100 81 = 81% Kojima-2000 935 742 = 79% Hospital Coroner, SCD 53 y 20 19 = 95% Friedman- 1973 Coroner, SCD <65 y 32 26 = 81% Tracy-1985 Med.exam, SCD <70 y 61 39 = 64% El Fawal-
  • 9. Plaque Rupture → Fatal Thrombosis acute MIacute MI ≈≈ sudden deathsudden death Patients Age n Rupture Study Hospital, ? ? 19 19 = 100% Chapman- 1965 Hospital, ? ? 17 17 = 100% Constantinides-1966 Hospital, AMI+SCD 58 y 40 39 = 98% Friedman- 1966 Hospital, AMI 62 y 88 71 = 81% Bouch-1970 Hospital, AMI 66 y 91 68 = 75% Sinapius- 1972 Hospital, AMI 67 y 76 69 = 91% Horie-1978 Hospital, AMI 67 y 49 40 = 82% Falk-1983 Hospital, AMI 83 52 = 63% Yutani-1987 Hospital, AMI 63 y 20 12 = 60% van der Wal- 1994 Hospital, AMI 69 y 291 218 = 75% Arbustini- 1999 Hospital, AMI 61 y 61 56 = 92% Shi-1999 Hospital, AMI 69 y 100 81 = 81% Kojima-2000 935 742 = 79% Acute MI Coroner, SCD 53 y 20 19 = 95% Friedman- 1973 Coroner, SCD <65 y 32 26 = 81% Tracy-1985 Med.exam, SCD <70 y 61 39 = 64% El Fawal-
  • 10. Plaque Rupture → Fatal Thrombosis age of deceasedage of deceased Patients Age n Rupture Study Hospital, ? ? 19 19 = 100% Chapman- 1965 Hospital, ? ? 17 17 = 100% Constantinides-1966 Hospital, AMI 83 52 = 63% Yutani-1987 Coroner, SCD? ? 85 71 = 84% Richardson- 1989 Coroner, SCD (all?) ? 202 143 = 71% Davies-1997, update 406 302 = 74% Age unknown Hospital, AMI 62 y 88 71 = 81% Bouch-1970 Hospital, AMI 66 y 91 68 = 75% Sinapius- 1972 Hospital, AMI 67 y 76 69 = 91% Horie-1978 Hospital, AMI 67 y 49 40 = 82% Falk-1983 Med.exam, SCD <70 y 61 39 = 64% El Fawal- 1987 Hospital, AMI 63 y 20 12 = 60% van der Wal- 1994 Hospital, AMI 69 y 291 218 = 75% Arbustini- 1999 Hospital, AMI 61 y 61 56 = 92% Shi-1999 Hospital, AMI 69 y 100 81 = 81% Kojima-2000 837 654 = 78% >60 years
  • 11. Plaque Rupture → Fatal Thrombosis sexsex Sex n Rupture Study p Male 37 32 = 86% Falk-1983 134 113 = 84% Davies-1997 184 151 = 82% Arbustini- 1999 .0004 74 63 = 85% Kojima-2000 .08 → .4 94 64 = 68% Virmani- 2000, update 523 423 = 81% Female 12 8 = 67% Falk-1983 27 16 = 59% Davies-1997 107 67 = 63% Arbustini- 1999 26 18 = 69% Kojima-2000 31 10 = 32% Virmani- 2000, update
  • 12. Plaque Rupture → Fatal Thrombosis sexsex && ageage Sex Age, y n Rupture Study Male >41, all 37 86% Falk- 1983 <50 7 86% ------------- +12 Females 50-70 22 82% ------------- >70 20 80% ------------- Male ~47 59 69% Burke-1997 unrelated to age
  • 13. Plaque Rupture → Fatal Thrombosis sexsex && ageage Sex Age, y n Rupture Study Male >41, all 37 86% Falk- 1983 <50 7 86% ------------- +12 Females 50-70 22 82% ------------- >70 20 80% ------------- Male ~47 59 69% Burke-1997 unrelated to age
  • 14. Plaque Rupture → Coronary Thrombosis burden of CHDburden of CHD *MI + fatal CHD. AHA 2002 Heart and Stroke Statistical Update. Annual heart attacks in the US: 1,107,000* • Men 668,000 Women, • ≥45 y 430,000 • <45 y 9,000 39% <1% 60%
  • 15. Plaque Rupture → Coronary Thrombosis burden of CHDburden of CHD Annual heart attacks in the US: 1,107,000 Plaque erosionPlaque erosion is the major substrate for thrombosis in premenopausal women. Burke et al. Am Heart J 2001 39% 60% ~1%
  • 16. Plaque Rupture → Coronary Thrombosis burden of CHDburden of CHD Annual heart attacks in the US: 1,107,000 Plaque erosionPlaque erosion is the major substrate for thrombosis in premenopausal women. Burke et al. Am Heart J 2001 Plaque rupturePlaque rupture is the major substrate in postmenopausal women and men ~1%
  • 17. Fatal Thrombosis: Rupture vs Non-rupture ageage && sexsex Rupture + - Study p Age, mean 53 y 44 y Farb-1996 <.02 68 y 70 y Arbustini- 1999 NS 69 y 71 y Kojima-2000 NS Male 48 y 45 y Burke-1997 NS
  • 18. Fatal Thrombosis: Rupture vs Non-rupture ageage && sexsex Rupture + - Study p Age, mean 53 y 44 y Farb-1996 <.02 68 y 70 y Arbustini- 1999 NS 69 y 71 y Kojima-2000 NS Male 48 y 45 y Burke-1997 NS
  • 19. Fatal Thrombosis: Rupture vs Non-rupture whites vs blackswhites vs blacks Rupture + - Study p Race Race was not significantly (p>0.4) associated with plaque rupture in men* *Burke AP et al. N Engl J Med 1997;336:1276-82
  • 20. Fatal Thrombosis: Rupture vs Non-rupture hypercholesterolemiahypercholesterolemia Rupture + - Study p Cholesterol Male mg/dlmg/dl 262 220 Burke-1997 .003 totaltotal::HDLHDL 8.5 5.0 Burke-1997 .003 Female mg/dlmg/dl 270 188 Burke-1998 .007 totaltotal::HDLHDL 6.2 6.0 Burke-1998 NS
  • 21. Fatal Thrombosis: Rupture vs Non-rupture hypertensionhypertension Rupture + - Study p Hypertension 22% 11% Burke-1997 NS 38% 22% Burke-1998 NS 56% 58% Kojima-2000 NS
  • 22. Fatal Thrombosis: Rupture vs Non-rupture diabetes mellitus ~ type 2diabetes mellitus ~ type 2 Rupture n + - Study p Diabetes 8 13% 33% Falk-1983 41 11% 64% Davies-1996, Circ 57 61% 42% Kojima-2000 NS GlycoHgb 59 7.9% 6.9% Burke-1997 NS
  • 23. Fatal Thrombosis: Rupture vs Non-rupture diabetes mellitus ~ type 2diabetes mellitus ~ type 2 Rupture n + - Study p Diabetes 8 13% 33% Falk-1983 41 11% 64% Davies-1996, Circ 5757 61%61% 42%42% Kojima-2000Kojima-2000 NSNS GlycoHgb 5959 7.9%7.9% 6.9%6.9% Burke-1997Burke-1997 NSNS
  • 24. Fatal Thrombosis: Rupture vs Non-rupture cigarette smokingcigarette smoking Rupture + - Study p Smokers 71% 83% Burke-1997 NS 50% 78% Burke-1998 NS 62% 26% Kojima-2000 .04
  • 25. Fatal Thrombosis: Rupture vs Non-rupture local flow and shearlocal flow and shear Rupture + - Study p Stenosis, mean area, %area, % 91 93 Falk-1983 NS 78 70 Farb-1996 <.03 77 70 Burke-1998 NS 76 70 Kojima- 2000 NS diameter, %diameter, % 39 64 Davies-
  • 26. Fatal Thrombosis: Rupture vs Non-rupture plaque calcificationplaque calcification Rupture + - Study p Calcification 69% 23% Farb-1996 .002
  • 27. Plaque Rupture → Fatal Thrombosis exertion and sudden deathexertion and sudden death Coronary thrombosis in men n Rupture Study Acute exertion + 19 89% Burke* - 51 53% -------- *Burke et al. JAMA 1999;281:921-26
  • 28. Coronary Thrombosis: Virchow’s triad pathogenesispathogenesis Local Systemic = Blo substrate flow coag.–plts.–fibr.lysis queque uptureupture +++ + on-ruptureon-rupture + +++ +++
  • 29. Coronary Thrombosis: Virchow’s triad therapytherapy Local Systemic = Blo substrate flow coag.–plts.–fibr.lysis queque uptureupture +++ + on-ruptureon-rupture + +++ +++ Statins ASA, clopidogrel, warfarin, etc. ? ?
  • 30. Coronary Thrombosis: Virchow’s triad therapytherapy Local Systemic = Blo substrate flow coag.–plts.–fibr.lysis queque uptureupture +++ + on-ruptureon-rupture + +++ +++ Statins ASA, clopidogrel, warfarin, etc. ? ? Additive?Additive?Additive?Additive?